COMPANY

MiNK Therapeutics

Keywords: cell therapy oncology immunology cancer Pneumonia Adult Respiratory Distress Syndrome Relapsed/Refractory Multiple Myeloma agenT-797

Location: New York, NY · source · Oct 12, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $307K (STTR Phase I 5R41AI192061-02, continuation, notice May 22, 2026). NIH RePORTER 5R41AI192061-02 (May 22, 2026)
Evidence (1 event)
- May 22, 2026 · NIH RePORTER 5R41AI192061-02
  Organization: MINK THERAPEUTICS INC; City/State: NEW YORK, NY; Project number: 5R41AI192061-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

May 26, 2026 Trial start Phase 2: A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure source ↗
Jun 2, 2025 Grant Government grant announced Jun 2, 2025. Source: company release on GlobeNewswire. source ↗
Jan 28, 2022 Trial start Phase 1: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors source ↗
Mar 29, 2021 Trial start Phase 1: agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma source ↗
Sep 21, 2020 Trial start Phase 1: A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS source ↗

2027-06 (ESTIMATED) · Phase 2 · A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure · NCT07615010

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Jun 2, 2025 Government grant announced Jun 2, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07615010	A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure	Phase 2	Recruiting	May 26, 2026	2027-06 (estimated)
NCT04582201	A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS	Phase 1	Completed	Sep 21, 2020	Apr 23, 2023 (actual)
NCT05108623	A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors	Phase 1	Completed	Jan 28, 2022	Jan 2, 2024 (actual)
NCT04754100	agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma	Phase 1	Completed	Mar 29, 2021	Jan 13, 2023 (actual)